Etcembly Ltd is a biotechnology company focused on engineering T cell receptors (TCRs) and antibodies based in Oxfordshire (UK).
T-cell receptor (TCR) therapies offer a powerful way to direct the immune system against cancer with fewer side effects than traditional treatments. Etcembly uses their groundbreaking machine learning platform, EMLy™, to engineer TCRs that target cancers with unmet treatment needs.
Traditional cancer treatments are often hindered by serious side effects due to lack of specificity, and T-cell receptor (TCR) therapies offer a targeted alternative by engaging the immune system to attack only cancer cells. However, developing effective TCRs is challenging due to time and cost constraints associated with conventional wet-lab methods. Etcembly seeks to accelerate this process by using machine learning to analyze extensive TCR datasets and generate numerous onco-specific TCRs.
In this project, they aim to integrate their current cell-based TCR activation assay with droplet microfluidics (Xdrop) to develop a massively parallel screening platform capable of identifying TCRs which respond to the target antigen at unprecedented throughput.
“By using the Samplix Xdrop we are able to generate double-emulsion droplets compatible with conventional cell sorting instruments; enabling us to incorporate single-cell phenotype screening within the droplet micro-environment, with increased throughput and reduced cell loss compared to single-emulsion technologies.”
Etcembly team with Xdrop: Matthew Jones, Principal Scientist; Chiara Moriconi, Senior Scientist; and Oliver Sampson, Scientist
“Our initial experience with the Xdrop has been excellent; there is minimal hands-on time. The speed and reproducibility with which it is able to produce single cell droplets will be critical as we develop our pipeline for mass-throughput TCR screening."
Dr. Oliver Sampson, Scientist
Learn more about Etcembly Ltd.
